Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease

  title={Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease},
  author={Leila H. Choe and M J Dutt and Norman Relkin and Kelvin H. Lee},
There is a need for a reliable, molecular‐based ante mortem diagnostic test for Alzheimer's disease (AD). In this study, we examined the use of two‐dimensional protein electrophoresis for generating molecular barcodes which may be useful for the clinical differentiation of AD patients from normals. We compared cerebrospinal fluid samples taken from AD patients with confirmed post mortem pathology to comparable specimens from normal volunteers. Using canonical correlation analysis, a panel of… 

Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease

These findings provide novel biomarker candidates for very mild and mild AD that can be further assessed as antecedent markers and predictors of clinical progression and when these biomarkers are optimally combined than when used individually.

Identification of Novel Fluid Biomarkers for Alzheimer's Disease

Levels of four novel biomarkers were significantly altered in AD, and Receiver-operating characteristic (ROC) analyses using a stepwise logistic regression model identified optimal panels containing these markers that distinguished CDR 0 from CDR>0 and CDR 1 fromCDR<1.

Biomarkers of Alzheimer's disease

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Present and the Future

The present state of the art and the future challenges in the search of CSF biomarkers for AD are discussed, highlighting the relevance of translational research for unbiased investigations of numerous putative markers that may be informative with regard to AD.

Proteome studies of CSF in AD patients

Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's disease

An elevated level of fibrinogen gamma-A chain precursor protein in CSF from patients with mild cognitive impairment and AD compared to the age-matched normal subjects was demonstrated and correlated with disease severity and progression.

Fibrinogen gamma-A chain precursor in CSF : a candidate biomarker for the progression of mild cognitive impairment to Alzheimer ’ s disease

The CSF-fibrinogen gamma-A chain precursor protein was elevated in the MCI group; its expression was more prominent in the AD group, and correlated with disease severity and progression.

The role of proteomics in dementia and Alzheimer’s disease

In this review, current proteomics technologies are described including many examples of clinical proteomics studies, which will lead to the design of several new Alzheimer’s disease-related protein panels for the analysis of CSF.